What’s going on with the Renalytix share price?

The Renalytix share price rose sharply yesterday but has still lost 90% in a year. Christopher Ruane looks into why and considers his next move.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It has been a horrible year to be a shareholder in kidney diagnostic specialist Renalytix (LSE: RENX). Over the past 12 months, the Renalytix share price has collapsed 90%. It jumped 15% yesterday, though at the time of writing this on Wednesday, it has been sliding again.

What is going on – and how ought I to respond as a shareholder?

Good news

The reason for yesterday’s jump was the release of some good news by the company.

A new study showed that patients in the early stages of diabetic kidney disease who were being treated with the company’s flagship KidneyIntelX tool received higher follow-up medical visit rates within a month than those who were not. That may suggest that the tool’s diagnostic capabilities enable quicker treatment than for patients whose kidney disease goes undiagnosed for longer.

This is the latest in a growing pile of research that provides a clinical basis for doctors to use the tool.

Bad news

However, fast forward 24 hours to today and things already look less positive for the business. Renalytix released its latest quarterly results and they contain a lot of red ink.

The period saw a net loss of $12m. Revenue was only $969,000. Although that is fairly modest, it is more than double what Renalytix achieved in the same period last year. So revenue growth far outstripped the 18% increase in net loss.

Nonetheless, the mismatch between revenues and losses is huge. Renalytix is spending vast sums of money to make relatively modest sales. In the long term, that is not a sustainable business model.

Looking to the future

I think that mismatch between the top and bottom lines of the company’s profit and loss account explains the implosion of the Renalytix share price over the past year.

Spending heavily may be necessary to build the sales base for the company’s products. But if it is spending far more than it is making in sales, it will not be profitable. Instead, it will burn even more cash, raising the risk of shareholder dilution or ultimately even bankruptcy.

The latest trading statement contained an outlook with disappointingly little forward-looking analysis. Rather defensively, in my view, it reminded readers that building scale for the company’s product sales involves a lot of work and “it sometimes seems this set of milestones takes a long time to accomplish”.

That sounds to me like a cloaked admission that business development is not moving at the same high pace as cash burn, which is obvious to anyone who looks at the company accounts.

Although the company announced plans in August to reduce annual expenditures by over $12m, in the most recent quarter its general and administrative expenses actually inched up.

The share price could fall further

At the end of September, the company had cash and cash equivalents of $31m. Liquidity is not an immediate risk, but if costs continue to outstrip revenues substantially, that will change.

I think Renalytix has powerful technology. The latest research further shows that it could be helpful for hospitals to adapt it. But the business model remains woeful. I am keeping my shares because it is hardly worth selling them at the current price, given the dealing fees involved. But I will definitely not be buying any more!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

C Ruane has positions in Renalytix AI plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »